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Summary
Objective: Prostaglandin E2 (PGE2) has been reported to stimulate chondrocyte differentiation. However, the precise actions and signal
transduction pathways of PGE2 in cartilage are largely unknown. Our purpose is to identify which of the four PGE2 receptor subtype(s),
EP1–4, mediates the action of PGE2 on chondrocyte differentiation.
Design: We used primary chondrocytes derived from the resting zone of rat rib cartilage. The effects on chondrocyte differentiation were
assessed by measuring the Alcian blue-stainable proteoglycan content and the expression levels of type II collagen mRNA by Northern blot
analysis. The expression of the four PGE2 receptor subtypes in rat primary chondrocytes was examined by reverse transcription-polymerase
chain reaction.
Results: PGE2 stimulated the accumulation of proteoglycan and up-regulated the expression of type II collagen mRNA in primary
chondrocytes. Dibutyryl cAMP, a cell-permeable analog of cAMP, an important intracellular mediator of PGE2 signaling, also enhanced the
expression of type II collagen mRNA and proteoglycan accumulation in chondrocytes. No EP agonist alone induced the expression of type
II collagen mRNA. However, simultaneous administration of EP2 and EP4 agonists at high concentrations cooperatively induced the
expression of type II collagen mRNA, mimicking the PGE2 effect. The simultaneous stimulation of EP2 and EP4 also cooperatively enhanced
proteoglycan accumulation and intracellular cAMP production. Moreover, an EP4 antagonist partially blocked the stimulatory actions of PGE2
on the expression of type II collagen mRNA.
Conclusion: These results suggest that simultaneous stimulation of EP2 and EP4 is necessary and sufficient to elicit the effect of PGE2 on
rat primary chondrocyte differentiation.
© 2003 Published by Elsevier Ltd on behalf of OsteoArthritis Research Society International.
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Introduction
Endochondral bone formation consists of diverse, distinct,
multistep cellular events contributed by chondrocytes,
osteoblasts, and osteoclasts in an orderly synchronized
manner. In the growth plate, resting chondrocytes undergo
a series of events that involve the transition to proliferating
chondrocytes characteristically expressing type II collagen
mRNA and accumulating proteoglycan onto the extra-
cellular matrix. Proliferating chondrocytes then differentiate
to hypertrophic chondrocytes, and coordinated bone forma-
tion by osteoblasts, and resorption of mineralized matrices
by osteoclasts, take place. Recent investigations have
significantly furthered our understanding of the molecular
mechanisms underlying this series of events. However,
these advances have not fully clarified the specific roles
that systemic and local factors play in these processes.
Prostaglandins (PGs) are a group of lipids produced from
arachidonic acid in a variety of cells under various physio-
logical and pathophysiological conditions. They act as
important regulators in a number of tissues including carti-
lage and bone. PGE2 is the most abundantly produced PG
and is of utmost importance in skeletal tissues1,2. PGE2
was initially described as a potent bone-resorbing sub-
stance3. However, several studies have demonstrated its
activity in the bone-forming processes4,5. Although many
studies have been published on the effects of PGE2 on
arthritic articular cartilage, several studies have reported
that PGE2 also makes an important contribution to cartilage
formation2,4,6. As reported previously, PGE2 promotes the
differentiation of rat growth plate chondrocytes6 and of the
chondrocyte cell line, RCJ 3.1C5.187, and, in vivo, cartilagi-
nous tissue mass was increased by PGE2 in a fracture
model8. In addition, cyclooxygenases are involved in the
synthesis of PGE2 and have a pivotal role in growth plate
development9, and indomethacin and other nonsteroidal
anti-inflammatory drugs reduce callus mass during the
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early stages of fracture repair10, delay fracture callus
formation11, and cause atrophic nonunion in animal
models12. Furthermore, there are pathological conditions,
such as osteophyte formation, which occur following in-
flammation and follow the processes of endochondral bone
formation. It is, therefore, essential that therapeutic drugs
be developed against such conditions to clarify the mech-
anism of PGE2 action. However, the precise action and
signal transduction pathway of PGE2 in chondrocyte
differentiation are largely unknown.
PGE2 exerts its effects through its interaction with
specific cell surface receptors, which are members of the
G-protein-coupled receptor family and consists of four
subtypes, EP1–4. The EP1–4 subtypes have been classi-
fied based on their distinct genes and signal transduction
pathways. EP1 is coupled to intracellular Ca2+ mobiliza-
tion13, EP2 and EP4 increase intracellular cAMP concen-
tration14,15, and EP3, which is reported to have three
isoforms, EP3α, β, and γ, mainly inhibits intracellular cAMP
accumulation16. It is conceivable that this diversity in signal
transduction through receptors is one reason why the
effects of PGE2 are not well understood. To clarify the
subtype-specific mechanism and to facilitate future thera-
peutic applications, we and our collaborators have shown
that EP4 is an essential receptor in bone formation17,18 and
bone resorption19,20 in terms of PGE2 action in bone. In
contrast, Sylvia et al.21 have shown that the EP1 receptor
subtype mediates various PGE2-induced cellular re-
sponses in chondrocytes derived from rat costochondral
cartilage leading to decreased proliferation and enhanced
differentiation. However, cAMP has been repeatedly re-
ported to play a crucial role in chondrocyte differentia-
tion6,22,23, and the functions of EP2 and EP4 remain to be
clarified. We have screened compounds on a panel of the
cloned receptors and developed agents that act specifically
at each EP subtype24. Using these tools, we report
here that the simultaneous stimulation of EP2 and EP4
is essential for the effects of PGE2 on chondrocyte
differentiation in rat primary chondrocytes.
Materials and method
MATERIALS
PGE2 was purchased from Cayman Chemical Company(Ann Arbor, MI). The EP1 agonist (ONO-DI-004), EP2
agonist (ONO-AE1-259-01), EP3 agonist (ONO-AE-248),
and EP4 antagonist (ONO-AE3-208) have been described
previously24–27. The specificities of the respective EP ag-
onists were analyzed by measuring the binding affinity of
the agonists to the respective EPs expressed in Chinese
hamster ovary (CHO) cells24–27. For an EP4 agonist, we
developed a more capable and stable compound, ONO-
AE1-437. ONO-AE1-437 is an active form (carboxylic acid)
of ONO-AE1-734 (methyl ester)27. The Ki values of the EP4
agonist, ONO-AE1-437, obtained by competition-binding
isotherms to displace the radioligand binding to the respec-
tive prostanoid receptor, are 0.7, 56, and 620 nM for EP4,
Fig. 1. Effect of PGE2 on Alcian blue-stainable proteoglycan content in growth plate chondrocytes. Cells were plated as described in
Materials and method section and cultured with varying doses of PGE2 (10−9, 10−8, 10−7, 10−6, or 10−5 M) for 6 days with medium
replacement every other day. Cells were then stained with Alcian blue (A) and Alcian blue-stainable proteoglycan content was determined
as described in Materials and method section (B). Values are means±SD of four wells, and are representative of three similar experiments.
*Statistically significant difference from the corresponding control group at p<0.05.
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EP3, and EP2, respectively, and more than 10 000 nM for
the other prostanoid receptors. The effect of the EP2 or
EP4 agonists on cAMP accumulation in the CHO cells
expressing each prostanoid receptor was analyzed by
measuring cellular cAMP concentrations using a [125I]
cAMP Assay Kit (Amersham Pharmacia Biotech, Aylesbury,
UK). Both agonists induced cAMP to levels similar to those
induced by PGE2 (data not shown). Dibutyryl cAMP (db-
cAMP) and the calcium ionophore, A23187, were obtained
from the Sigma Chemical Co. (St. Louis, MO).
CHONDROCYTE CULTURE
Growth plate chondrocytes were isolated from the rib
cartilages of 5-week-old male Wistar rats that weighed
between 120 and 140 g as described by Shimomura
et al.28. Briefly, the resting zones of the rib cartilages were
minced and incubated with 0.1% ethylenediamine tetra-
acetic acid/phosphate-buffered saline (PBS) without Ca2+
or Mg2+ for 20 min at 37°C. The cartilage was then digested
successively with 0.2% trypsin/PBS for 1 h at 37°C (trypsin
from Invitrogen Corporation, Carlsbad, CA), and 0.2%
collagenase (Wako Pure Chemical Industries, Ltd, Osaka,
Japan) for 6 h at 37°C. Freshly isolated chondrocytes were
suspended in Dulbecco’s modified Eagle’s medium/Ham’s
F-12 hybrid medium (ICN Biomedicals, Inc., Aurora, OH)
containing 10% fetal bovine serum (Cansera International
Inc., Rexdale, Canada) and 50 µg/ml ascorbic acid (Wako
Pure Chemical Industries, Ltd). We plated chondrocytes in
6- or 24-well plastic plates (Corning Inc., Corning, NY) and
cultured these cells at 37°C in a humidified 5% CO2/95%
air atmosphere with medium replacement every other day.
All experiments were begun 24 h after the final change of
medium when the cells became confluent. Under these
experimental conditions, cells expressed type II collagen
mRNA and accumulated Alcian blue-stainable proteo-
glycan, both of which are markers for chondrocytes, and
did not express transcripts of type X collagen, a marker for
hypertrophic chondrocytes.
MEASUREMENT OF CARTILAGE-SPECIFIC PROTEOGLYCAN
Chondrocytes were plated in 24-well plastic plates at an
initial density of 5×104 cells/well and cultured with medium
replacement every other day. We treated cells with test
substances 24 h after the final change of medium when the
cells became confluent. We continued to culture the cells
with medium replacement every other day, and the test
substances were added to the medium at every replace-
ment. After an additional 6-day incubation, cells were
rinsed twice with PBS, fixed with methanol for 30 min at
room temperature, rinsed once with distilled water, and
then stained overnight at room temperature with 0.1%
Alcian blue (Alcian blue 8 GX, Sigma Chemical Co.) in
Fig. 2. Effects of PGE2 on the transcript levels of type II collagen in
growth plate chondrocytes. Cells were plated as described in
Materials and method section and were then exposed for an
additional 48 h to varying doses of PGE2 (10−9, 10−8, 10−7, 10−6, or
10−5 M) or vehicle. Total RNA was prepared and subjected to
Northern blot analysis (20 µg of total RNA per lane). The signal
intensities of type II collagen (α1(II)) mRNAs were measured and
normalized against those of corresponding β-actin mRNAs, as
described in Materials and method section. The top panel shows
type II collagen and β-actin mRNA bands. The bottom panel shows
relative levels of the type II collagen mRNAs normalized against
those of β-actin mRNAs (in % of controls, mean±SD). Values are
means±SD of three independent experiments. *Statistically signifi-
cant difference from the corresponding control group at p<0.05.
Fig. 3. Effects of dbcAMP on the transcript levels of type II collagen
in growth plate chondrocytes. Cells were plated as described in
Materials and method section and were then exposed for an
additional 48 h to varying doses of dbcAMP (0.01, 0.1, 0.3, or
0.45 mM) or vehicle. Total RNA was prepared and subjected to
Northern blot analysis (20 µg of total RNA per lane). The signal
intensities of type II collagen (α1(II)) mRNAs were measured and
normalized against those of corresponding β-actin mRNAs, as
described in Materials and method section. The top panel shows
type II collagen and β-actin mRNA bands. The bottom panel shows
relative levels of the type II collagen mRNAs normalized against
those of β-actin mRNAs (in % of controls, mean±SD). Values are
means±SD of three independent experiments. *Statistically signifi-
cant difference from the corresponding control group at p<0.05.
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0.1 N HCl. Cells were rinsed three times with distilled water,
and the amount of cell-associated dye was measured
at 620 nm after extraction with 6 M guanidine–HCl
(400 µl/well)29.
RNA EXTRACTION AND NORTHERN BLOT ANALYSIS OF TYPE II
COLLAGEN mRNA
Chondrocytes were plated in 6-well plastic plates at an
initial density of 12×104 cells/well and cultured. We treated
cells with test substances 24 h after the final change of
medium when the cells became confluent. Forty-eight
hours after treatment, total RNA was prepared from the
cultures by the single-step method using Trizol (Invitrogen
Corporation). For Northern hybridization, total RNA (20 µg)
was denatured, separated by 1% agarose gel electrophore-
sis, and transferred onto Nytran membranes (Schleicher
and Schuell, Dassel, Germany) as described previously30.
Hybridization probes were prepared by the random-primer
method with a BcaBEST Labeling Kit (Takara, Ohtsu,
Japan). After hybridization, the membranes were exposed
to X-Omat film (Kodak, Rochester, NY) at −80°C with
Cronex Lightening Plus intensifying screens (Dupont,
Boston, MA). Hybridization signals were quantified densi-
tometrically using an optical scanner and microcomputer.
The signal intensities of type II collagen mRNAs were
normalized against those of corresponding β-actin mRNAs.
REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
ANALYSIS
Reverse transcription-polymerase chain reaction (RT-
PCR) was performed as described previously30. Briefly,
first-strand cDNA was synthesized using SuperScript II
RNase H-reverse transcriptase (Invitrogen Corporation)
with 5 µg total RNA extracted from chondrocytes cultured
as described earlier. EP primers used were: EP1 sense,
5′-CAA CAC TGT CAC AGC ACT GG-3′, and EP1 anti-
sense, 5′-GGT ACAAGG TGT TGA GAT TC-3′; EP2 sense,
5′-CGT GTA CCT ATT TCG CTT TC-3′, and EP2 antisense,
5′-GAG GTC CCA CTT TTC CTT TC-3′; EP3 sense,
5′-CCG GAG CAC TCG GTT GAA GC-3′, and EP3 anti-
sense, 5′-CGA ACA CTG TCA TGG TCA GC-3′; EP4
sense, 5′-GAG GTG GTG TCT GCT TGG GTC AG-3′, and
EP4 antisense, 5′-AGG ATT GCT TCT GTG AAC CCC
AT-3′. The expected product sizes were 298 base pairs
(EP1), 568 base pairs (EP2), 334 base pairs (EP3), and
335 base pairs (EP4). Aliquots (8 µl) of each PCR product
were resolved on 3% NuSieve 3:1 agarose gels (Bio
Whittaker Molecular Applications, Rockland, ME) alongside
markers.
ASSAY OF cAMP PRODUCTION
To measure the amount of cAMP produced, chondro-
cytes were plated in 24-well plastic plates at an initial
density of 5×104 cells/well and cultured with medium re-
placement every other day. We treated cells with test
substances 24 h after the final change of medium when the
cells became confluent, and then incubated them for 7 min
at 37°C. Cells were lysed, and the cellular cAMP content
was determined with a cAMP enzyme immunoassay kit
(Cayman Chemical Company).
STATISTICAL ANALYSIS
Differences between groups were analyzed by one-way
analysis of variance (ANOVA) using the Stat-View soft-
ware package (SAS Institute Inc., Cary, NC). Significant
differences were set at p<0.05.
Results
PGE2 STIMULATES THE ACCUMULATION OF ALCIAN
BLUE-STAINABLE PROTEOGLYCAN AND UP-REGULATES THE
EXPRESSION OF TYPE II COLLAGEN mRNA IN PRIMARY RAT
CHONDROCYTES
Several lines of conflicting evidence have been reported
on the effects of PGE2 in chondrocyte differentiation.
Therefore, we first examined the effects of PGE2 on the
accumulation of cartilage-specific proteoglycan and the
expression of type II collagen mRNA in primary chondro-
cytes derived from the resting zone of rat costochondral
cartilage. PGE2 significantly stimulated proteoglycan syn-
thesis in a dose-dependent manner (Fig. 1). Next, we
assessed the effects of PGE2 on the transcript levels of
Fig. 4. RT-PCR analysis of the expression of EP receptor mRNAs in growth plate chondrocytes. Reverse-transcribed products were amplified
with the appropriate primers for each EP subtype or GAPDH, as described in Materials and method section. A 100-bp ladder used as a
molecular marker is indicated on the left. C, growth plate chondrocytes; K, kidney; L, lung; M, markers.
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type II collagen, which is considered a crucial gene for
chondrocyte differentiation. Exogenously administered
PGE2 increased the transcript levels of type II collagen
mRNA in chondrocytes in a dose-dependent manner
(Fig. 2).
dbcAMP MIMICS THE EFFECTS OF PGE2 ON THE EXPRESSION OF
TYPE II COLLAGEN mRNA IN CHONDROCYTES
PGE2 stimulates the intracellular production of cAMP.
Therefore, we also examined the effects of exogenously
administered dbcAMP, a cell-permeable analog of cAMP,
on the transcript levels of type II collagen using Northern
blot analysis. The expression of type II collagen mRNA
increased in cells treated with 0.3 mM dbcAMP (Fig. 3),
whereas the transcript levels decreased in cells treated
with 0.1 mM dbcAMP. Moreover, dbcAMP enhanced the
accumulation of Alcian blue-stainable proteoglycan (data
not shown). On the other hand, although intracellular
calcium is reportedly increased by PGE2 treatment, the
calcium ionophore A23187, which increases intracellular
calcium, elicited no effect on type II collagen mRNA expres-
sion or on the synthesis of proteoglycan (data not shown).
EP1, EP2, AND EP4 mRNAS ARE EXPRESSED IN PRIMARY RAT
CHONDROCYTES
Previously, only the expression of EP1 and EP2 has
been reported in primary chondrocytes derived from rat
rib21. However, to understand the molecular mechanisms
underlying the action of PGE2 in cartilage, it is critical to
elucidate which receptors are expressed in chondrocytes.
EP1, EP2, and EP4 receptor transcripts were detected in
the growth plate chondrocytes by RT-PCR (Fig. 4). These
products were directly sequenced and confirmed to be
EP1, EP2, and EP4 by comparison with published rat EP1,
EP2, and EP4 sequences. No products were amplified with
the EP3 receptor primer set, although the expected EP3
cDNA fragment was amplified from RNA extracted from
lung.
EP2 AND EP4 AGONISTS COOPERATIVELY UP-REGULATE THE
EXPRESSION OF TYPE II COLLAGEN mRNA AND STIMULATE THE
ACCUMULATION OF ALCIAN BLUE-STAINABLE PROTEOGLYCAN IN
CHONDROCYTES
PGE2 increases the concentration of intracellular cAMP
via its binding to EP2 and EP4 receptors. We have pre-
viously reported that EP4 is a receptor essential to the
action of PGE2 on both osteoclast and osteoblast acti-
vation. Based on the above results, we expected that PGE2
would act through EP2 and/or EP4 in affecting chondrocyte
Fig. 5. Effects of EP2 and EP4 agonists on the transcript levels of
type II collagen in growth plate chondrocytes. Cells were plated as
described in Materials and method section and then exposed for
an additional 48 h to either different doses of EP2 agonist (10−9,
10−8, 10−7, 10−6, or 10−5 M) (A) or EP4 agonist (10−10, 10−9, 10−8,
10−7, or 10−6 M) (B) or vehicle. Total RNA was prepared and
subjected to Northern blot analysis (20 µg of total RNA per lane).
The signal intensities of type II collagen (α1(II)) mRNAs were
measured and normalized against those of corresponding β-actin
mRNAs, as described in Materials and method section. The top
panel shows type II collagen and β-actin mRNA bands. The bottom
panel shows relative levels of the type II collagen mRNAs normal-
ized against those of β-actin mRNAs (in % of controls, mean±SD).
Values are means±SD of three independent experiments.
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differentiation. To examine which PGE receptor mediates
the effects of PGE2 on the expression of type II collagen
mRNA, we developed the EP agonists described earlier,
treated chondrocytes with them, and examined the type II
collagen transcript levels by Northern blot analysis. No
agonist alone induced the expression of type II collagen
mRNA (Fig. 5). On the other hand, stimulation with the EP2
agonist at a high concentration in the presence of the EP4
agonist induced the expression of type II collagen mRNA
[Fig. 6(A)], mimicking the effect of PGE2. Stimulation with
the EP4 agonist in the presence of the EP2 agonist also
enhanced this expression (data not shown). No other
combination of stimulants caused up-regulation of type II
collagen mRNA expression (data not shown). Moreover,
Fig. 6. Effects of EP2 agonist in the presence of EP4 agonist on the
transcript levels of type II collagen (A) and Alcian blue-stainable
proteoglycan content (B) in growth plate chondrocytes. (A) Cells
were plated as described in Materials and method section and then
exposed for an additional 48 h to varying doses of EP2 agonist
(10−9, 10−8, 10−7, or 10−6 M) in the presence of EP4 agonist
(10−6 M). Total RNA was prepared and subjected to Northern blot
analysis (20 µg of total RNA per lane). The signal intensities of type
II collagen (α1(II)) mRNAs were measured and normalized against
those of corresponding β-actin mRNAs as described in Materials
and method section. The top panel shows type II collagen and
β-actin mRNA bands. The bottom panel shows relative levels of the
type II collagen mRNAs normalized against those of β-actin
mRNAs (in % of controls, mean±SD). Values are means±SD of
three independent experiments. *Statistically significant difference
from the corresponding control group at p<0.05. (B) Cells were
plated as described in Materials and method section and cultured
with PGE2 (10−5 M), EP2 agonist (10−6 M), EP4 agonist (10−6 M),
EP2 agonist (10−6 M) plus EP4 agonist (10−6 M) or vehicle for 6
days with medium replacement every other day. Cells were then
stained with Alcian blue and Alcian blue-stainable proteoglycan
content was determined as described in Materials and method
section. Values are means±SD of four wells, and are represen-
tative of three similar experiments. *Statistically significant
difference from the corresponding control group at p<0.05.
Fig. 7. Effects of EP2 and EP4 agonists on cAMP production in
growth plate chondrocytes. Cells were plated as described in
Materials and method section and then exposed for an additional
7 min to PGE2 (10−5 M), EP2 agonist (10−6 M), EP4 agonist(10−6 M), EP2 agonist (10−6 M) plus EP4 agonist (10−6 M) or
vehicle. Cellular cAMP was measured as described in Materials
and method section. Values are means±SD of four wells, and are
representative of three similar experiments. *Statistically signifi-
cant difference from the corresponding control group at p<0.05.
**Statistically significant difference from the group treated with EP2
agonist or the group treated with EP4 agonist at p<0.05.
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the simultaneous addition of the EP2 and EP4 agonists
cooperatively enhanced the accumulation of Alcian blue-
stainable proteoglycan [Fig. 6(B)].
EP2 AND EP4 AGONISTS COOPERATIVELY INDUCE cAMP
PRODUCTION IN CHONDROCYTES
PGE2 elicited cAMP production in chondrocytes, and
cAMP stimulated chondrocyte differentiation as described
earlier. Therefore, an examination of the effects of EP
agonists on cAMP production in chondrocytes was pivotal
to our analysis of PGE2-induced chondrocyte differentia-
tion. As reported previously in primary osteoblasts24,
simultaneous addition of the EP2 and EP4 agonists
cooperatively stimulated cAMP production (Fig. 7).
THE EP4 ANTAGONIST BLOCKS THE ACTION OF PGE2 IN
STIMULATING CHONDROCYTE DIFFERENTIATION
To confirm that EP4 antagonists can block the action of
PGE2 in stimulating differentiation in growth plate chondro-
cytes, we added the EP4 antagonist, ONO-AE3-208, to
chondrocytes treated with PGE2. The EP4 antagonist par-
tially inhibited the enhancement by PGE2 of type II collagen
mRNA expression (Fig. 8) and the accumulation of
proteoglycan synthesis in a dose-dependent manner (data
not shown).
Discussion
In the present study, we demonstrated that both EP2 and
EP4 mediate the stimulation of chondrocyte differentiation
by PGE2. We provide two lines of evidence that PGE2
enhances chondrocyte differentiation: PGE2 increased pro-
teoglycan accumulation and up-regulated the expression of
type II collagen mRNA in a dose-dependent manner in
primary rat chondrocytes (Figs. 1 and 2). Although other
markers such as alkaline phosphatase, Ch21 protein31,
Ex-FABP32, and Patched33 have also been reported to be
indicators of chondrocyte differentiation, type II collagen
mRNA expression and accumulation of proteoglycan are
two of the most powerful indicators. Thus, we conclude
from our and others’ studies2,6,22, that PGE2 enhances
growth plate chondrocyte differentiation. Indeed, PGE2
showed stimulatory effects on the expression of alkaline
phosphatase mRNA in a similar manner (data not
shown).
Using agents that act receptor-subtype-specifically, we
found that neither ONO-AE1-259-01, an EP2 agonist, nor
ONO-AE1-437, an EP4 agonist, individually up-regulated
the expression of type II collagen mRNA, even at high
concentrations (Fig. 5). On the other hand, these two
agonists cooperatively up-regulated type II collagen
expression and enhanced the accumulation of Alcian
blue-stainable proteoglycan (Fig. 6) when administered
simultaneously. The differentiation-stimulating effects of
PGE2 were also partially blocked by ONO-AE3-208, an
EP4 antagonist (Fig. 8). In contrast, neither the stimulation
of EP1 nor the stimulation of EP3 affected the expression of
type II collagen mRNA (data not shown). These lines of
evidence collectively suggest that binary stimulation of EP2
and EP4 is necessary and sufficient to elicit the effect of
PGE2 on chondrocyte differentiation.
In terms of intracellular signaling, this conclusion is
supported by evidence that cell-permeable dbcAMP can
mimic the effects of PGE2 on type II collagen mRNA
expression and proteoglycan production. These data
prompt us to propose the hypothesis that cAMP is an
essential second messenger for the action of PGE2 in
chondrocyte differentiation. Indeed, we clearly showed that
EP2 and EP4 agonists increase the intracellular cAMP
concentrations in a cooperative manner in primary
chondrocytes (Fig. 7), as reported previously in primary
osteoblasts24. Although the EP2 and EP4 agonists used
here induced concentrations of cAMP as high as those
induced by PGE2 in the CHO cells expressing each recep-
tor subtype (data not shown), neither agonist induced a
level of cAMP similar to that induced by PGE2 in primary
chondrocytes. This difference is presumably cell-type
specific. It is therefore necessary to develop agents that
can also induce sufficient amounts of cAMP in these types
of cells, both to facilitate therapeutic applications and to
further our understanding of the action of PGE2.
On the other hand, Sylvia et al.21 have reported that rat
primary chondrocytes express EP1 and EP2, not EP3 or
EP4, and that the EP1 receptor subtype mediates various
PGE2-induced cellular responses, leading to decreased
Fig. 8. Reversal by EP4 antagonist of the stimulatory actions of
PGE2 on the expression of type II collagen mRNA in growth plate
chondrocytes. Cells were plated as described in Materials and
method section and then exposed for an additional 48 h to varying
doses of EP4 antagonist (10−8, 10−7, 10−6, or 10−5 M) in the
presence of PGE2 (10−5 M). Total RNA was prepared and sub-jected to Northern blot analysis (20 µg of total RNA per lane). The
signal intensities of type II collagen (α1(II)) mRNAs were
measured and normalized against those of corresponding β-actin
mRNAs, as described in Materials and method section. The top
panel shows type II collagen and β-actin mRNA bands. The bottom
panel shows relative levels of the type II collagen mRNAs normal-
ized against those of β-actin mRNAs (in % of controls, mean±SD).
Values are means±SD of three independent experiments.
*Statistically significant difference from the corresponding control
group at p<0.05.
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proliferation and enhanced differentiation. This discrepant
finding may be derived from differences between the
passage numbers of the chondrocytes used. Although
chondrocytes at the fourth passage sufficiently retain their
chondrogenic phenotype and responsiveness to important
factors shown in their studies, it has been reported that the
passage number may affect the nature of chondrocytes. An
elaborate expression study in situ and manipulative studies
in vivo will help us clarify further the expression of PGE2
receptor subtypes and their roles in the growth plate
chondrocytes.
In the present study, PGE2 showed a biphasic-like effect
on the expression of type II collagen mRNA, as has been
reported previously in osteoblasts5,18 and chondrocytes7. It
is noteworthy that cAMP itself can induce biphasic effects
similar to those of PGE2 without the contribution of other
factors, supporting our hypothesis that cAMP plays a
pivotal role in the action of PGE2 on chondrocytes. This
biphasic activity of cAMP could underlie the multiplicity of
PGE2 effects but this remains to be proved.
EP2 stimulation down-regulated the transcript levels of
type II collagen at a high concentration, whereas EP4
stimulation did not, although both agonists are similarly
able to induce cAMP. It is suggested that not only cAMP
but also other intracellular mechanisms contribute to this
process, and that EP2 signaling has a main role in the
down-regulation of type II collagen expression. Intracellular
calcium is not a candidate factor for this role, as we showed
in the present study (data not shown). Furthermore, EP2
and EP4 have different actions in osteoblasts and
osteoclasts17–20. Therefore, how each agonist participates
in the action of PGE2 within the cell is a fundamental and
interesting question.
Our collaborators have generated mice deficient in each
EP subtype as genetic tools, as reported previously34–36.
Neither EP2- nor EP4-deleted mice showed significant
changes in growth plate morphology20,37. One possible
reason is that the sole deletion of EP2 or EP4 is insufficient
to cause significant detrimental effect on growth plates and
mice with a double knockout of EP2 and EP4 may exhibit
developmental impairment to cartilage.
As has been frequently reported, prostaglandins includ-
ing PGE2 play critical roles in pathophysiological condi-
tions. A number of investigations have revealed the role
that PGE2 plays in arthritic cartilage. Cultured chondro-
cytes from osteoarthritic joints show increased PGE2
production and cyclooxygenase activity38. Furthermore,
PGE2 has apoptotic activity in these pathological carti-
lages39. However, in terms of its action in chondrocyte
differentiation, PGE2 may accelerate the osteophyte forma-
tion that is frequently seen in arthritic joints and which
occurs by the processes of endochondral bone formation.
Moreover, heterotopic ossification, which also follows the
process of endochondral ossification, can be prevented
by indomethacin40–42. Patients who develop heterotopic
ossification after spinal cord injury show a concomitant
marked increase in PGE2 urinary secretion within 24 h of
injuries43. Further clarification of the respective role that
each receptor subtype plays in chondrocyte differentiation
is necessary to develop agents that prevent the harmful
effects and accelerate the desirable actions of PGE2. The
speculations presented here, based on our findings, are
yet to be proven, and therapeutic strategies should be
investigated in the future.
In summary, simultaneous stimulation of EP2 and EP4 is
necessary and sufficient to elicit the effects of PGE2 in
primary rat chondrocyte differentiation.
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